text:
Maj.-Gen. Dany Fortin leaves the Gatineau Police Station after being processed, in Gatineau, Que., on Wednesday, Aug. 18, 2021. THE CANADIAN PRESS/Justin Tang
Military officer who led vaccine campaign faces sexual assault charge
Dany Fortin told reporters that he does not know the details of the allegation against him
The military officer who led Canada's COVID-19 vaccine distribution campaign has been charged with one count of sexual assault.
Maj.-Gen. Dany Fortin presented himself to police in Gatineau, Que., on Wednesday morning after a warrant for his arrest was issued Monday.
He later told reporters that he does not know the details of the allegation against him, despite repeated requests from his legal team.
"For the past three months, my family and I have been living this nightmare of not knowing the nature of the allegation, not knowing the status of the investigation, not knowing whether or not I'd be charged," Fortin said.
"My legal team has repeatedly — repeatedly — contacted prosecutors to seek any information with no success. So I've been forced to read much about me in media, with no ability to defend my name."
Fortin's lawyers have said the only information provided to them is that the charge relates to an alleged incident from 1988.
The senior military officer, who has previously served in Afghanistan and Iraq, described the past three months as the most challenging period of his 36 years in uniform.
"This fight against an invisible foe has been the hardest of my career," he said. "I look forward to continuing to serve Canadians, to serve my country, as soon as this legal issue is resolved."
Fortin was abruptly removed from his post at the Public Health Agency of Canada on May 14 after leading the distribution of COVID-19 vaccines across the country.
The Canadian Forces National Investigation Service later referred an allegation of sexual misconduct against him to the Quebec prosecution service to determine whether charges should be laid.
Fortin has asked the Federal Court to review his removal, alleging in a sworn affidavit political interference by the Liberal government. He is asking for reinstatement to his position at PHAC, or a similar post.
The military officer said Wednesday he is paying his own legal costs for the criminal and Federal Court actions. His next court appearance is scheduled for Sept. 20, the same day that voters go to the polls.
Liberal Leader Justin Trudeau declined to comment on Fortin's case during a campaign stop in Vancouver on Wednesday.
"But I will repeat how incredibly important it is that everyone who serves in the Canadian Armed Forces has an environment that is safe and supportive," the prime minister said.
"We need to make sure that anyone who comes forward with allegations or with concerns is receiving the proper support, the proper resources. But at the same time that we work to transform the culture of our Canadian Armed Forces."
One of Fortin's lawyers has raised questions about the timing of the decision to charge her client, which comes days after Liberal Leader Justin Trudeau launched an election.
The Liberals have been criticized for months for not doing more to address sexual misconduct in the Canadian military.
Fortin's lawyers have argued in Federal Court that the decision to remove their client was unreasonable, lacked procedural fairness and involved improper political interference in the military chain of command by Trudeau, Health Minister Patty Hajdu, Defence Minister Harjit Sajjan and clerk of the Privy Council.
The government is required to respond to those allegations on Sept. 17, three days before election day.
"The timing of the charge raises questions," Fortin's lawyer, Natalia Rodriguez, told The Canadian Press on Tuesday.
"We'll be looking at answering those questions and making sure this is not politically motivated and that it is above board. As Maj.-Gen. Fortin's lawyers, we have a duty to ensure that there's been no improper political interference in this case."
In response, Sajjan's spokesman Daniel Minden on Wednesday said: "In Canada, decisions to lay criminal charges are made by independent prosecutors. We have no further comment as this matter is before the courts."
Conservative Leader Erin O'Toole also declined to comment on the charge against Fortin because the issue is before the courts, but used the opportunity to once again criticize the Liberals' handling of sexual misconduct allegations in the military.
Fortin is the second senior military officer to be charged with a criminal offence in recent weeks after the CFNIS charged former defence chief Jonathan Vance with one count of obstruction of justice last month.
That followed an investigation into allegations Vance engaged in inappropriate sexual behaviour before and after he became chief of the defence staff in July 2015. He has denied any wrongdoing and not been charged in connection with those allegations.
The Liberal government is also in a standoff with Vance's successor as defence chief, Admiral Art McDonald, who last week declared his intention to return to his position after a military police investigation into his conduct resulted in no charges.
The government responded by ordering McDonald to remain on administrative leave and promoting acting defence chief Gen. Wayne Eyre in a sign that it plans to keep the latter as commander of Canada's military.
— with files from Maan Alhmidi in Gatineau, Que.
Lee Berthiaume, The Canadian Press
RELATED: Defence chief's notes reveal debate over due process, optics on Fortin allegation
Canadian Forces sexual assaultCoronavirusMilitary
'See it as a call to action': B.C. scientists rally behind UN climate change report
Golden Life regional manager loses nursing license for three years


At Inter-Personal Group we can handle your financial planning and tax preparation needs under one roof.
We help you integrate your finances and your goals so that the life journey ahead is what you would like it to be.
Your SARS tax compliance responsibility becomes our responsibility giving you peace of mind.
We operate with integrity, honesty and we are open and direct in our dealings.
We provide our clients with a professional, dedicated, value added quality service.
We are resourceful, adaptable and results driven.
We strive for excellence in all we do and keep things simple and clear.
We are service oriented, responsive, and do what we say.
We give our clients much more value than what they pay for.
We abide by all applicable laws, rules, regulations, and administrative practices.
We treat our clients, staff, and associates with dignity, respect, and trust.
We actively protect the confidentiality of our clients and our business.
We are committed to returning calls and e-mail messages ASAP and certainly within 48 hours.
We strive for results with a strong sense of urgency.
It is a known fact that there is a serious lack of knowledge about personal finance and income tax. We take the time to explain the essential basics that may impact our clients.


text:
Some M1 iPad Pro Orders Start Switching to 'Shipped' Status With May 21 Delivery
Thursday May 13, 2021 3:23 am PDT by Sami Fathi
Ahead of their expected launch on May 21, some brand new M1 iPad Pro orders have begun switching to a "Shipped" status.
Multiple readers of MacRumors have shared with us their updated order for their brand new iPads which now shows a "Shipped" status, rather than "Preparing to ship." Interestingly, despite the new iPad Pros now shipping for a few customers, reviews and hands-on of the newest M1-powered device have yet to be published.
The new iPad has proven to be popular, with some shipping estimates slipping into mid-July. The higher-end 12.9-inch model features an all-new mini-LED display compared to the traditional LED display used in the smaller 11-inch variant. Both sizes boast the Apple silicon M1 chip, first launched in November in the MacBook Air, MacBook Pro, and Mac mini.
Apple has said the new M1 iPad Pro and 24-inch iMac will be available in the second half of May but have yet to confirm a specific date officially. Despite their lack of an official announcement, typically made through a Newsroom update, the company accidentally confirmed May 21 as a launch date in the metadata of a previous Newsroom post. In addition, orders for the new iPad estimated arrival dates as early as Friday, May 21.
Related Roundup: iPad Pro
Buyer's Guide: 11" iPad Pro (Neutral), 12.9" iPad Pro (Neutral)
Related Forum: iPad
[ 178 comments ]
Aluminum213
It's going to be so exciting to use the M1 chip to run one app at a time!!!!
jom3500
Is really no one going to mention that the article says, the 11" is using OLED? xd
lyngo
I received the "item has shipped" email today. Here we go! Right now it's in China and on its way to its home. Space Grey - 256GB - 5G device on route!
kycophpd
I'm confused guys. Both Pro colors look good and recently I'm leaning towards silver. Should I get the silver?
I personally wouldn't let the internet decide on a very expensive purchase. I would decide myself. Maybe it's just me? What do you think? Is it just me?
jwill99
Both of our M1 iPad Pros 512gb have shipped and have a delivery date of Friday, May 21st.
Apple Ramping Up M1 Production as New 12.9-inch iPad Pro Expected to Reach Five Million Shipments in 2021
Thursday April 22, 2021 2:19 am PDT by Sami Fathi
Apple is seemingly expecting high demand for its new M1-powered iPad Pro as the company has asked its main chip supplier, TSMC, to ramp up production of the chip for its new iPad, and newer Mac computers, according to industry sources cited by DigiTimes. Earlier this week, Apple unveiled a brand new 11 and 12.9-inch iPad Pro powered by the M1 Apple silicon chip, the same chip powering the new...
Apple's Greg Joswiak: No Plans to Merge Mac and iPad
Thursday April 22, 2021 2:09 pm PDT by Juli Clover
Apple earlier this week introduced refreshed 11 and 12.9-inch iPad Pro models with few external changes but one notable internal change - the introduction of the same M1 chip that was also used in the MacBook Pro, MacBook Air, and Mac mini refreshes back in November. Apple marketing chief Greg Joswiak and hardware chief John Ternus this week did an interview with The Independent to talk...
See the Dramatic Improvement Mini-LED Brings to the M1 iPad Pro's Display
Tuesday May 25, 2021 12:26 pm PDT by Juli Clover
Aside from the M1 chip, Apple's 12.9-inch 2021 iPad Pro models have one other standout feature - the new mini-LED display. It's the best ever display used in an iPad, and there's such a stark difference between the mini-LED display and the display of the 2020 iPad Pro that we had to show it off. Subscribe to the MacRumors YouTube channel for more videos. The iPad Pro's mini-LED display, which ...
Shipping Estimates for 12.9-Inch Mini-LED iPad Pro Slip to July
Friday April 30, 2021 11:31 am PDT by Juli Clover
Prior to the launch of the new iPad Pro models, rumors suggested that the 12.9-inch iPad Pro would be in short supply, and it appears those rumors were correct. Shipping estimates for 12.9-inch iPad Pro models now range into July for orders placed today, though the highest-end 2TB model is still available for June delivery. 128GB, 256GB, 512GB, and 1TB models have delivery estimates of...
Leaker Claims 11-inch iPad Pro to Ship on May 22, 12.9-inch on May 21
Monday April 26, 2021 5:23 am PDT by Sami Fathi
Last week Apple announced brand new updates to its 11-inch and 12.9-inch iPad Pro with the faster M1 processor and a brand new mini-LED 12.9-inch display. Both models will become available for pre-order starting on April 30, and Apple says they'll be shipping in the second half of May. Now, according to Apple leaker Jon Prosser, the 11-inch iPad Pro, which features a faster M1 processor and...
M1 iPad Pro Arrives Early for Lucky Customer
Saturday May 15, 2021 11:57 pm PDT by Sami Fathi
Days ahead of their expected launch and seemingly before official review embargoes lift, one lucky customer has already gotten their hands on the brand new 12.9-inch M1 iPad Pro. Reddit User PeterDragon50 Posted on Reddit, u/PeterDragon50 has already received their 12.9-inch iPad Pro through retailer Nebraska Furniture Mart. The Reddit user says they placed their order when pre-orders...
UK Retailer John Lewis Lists iPad Pro and iMac Launch Date as May 21
Thursday April 29, 2021 1:03 am PDT by Tim Hardwick
Last week Apple announced new iPad Pro models with the faster M1 processor and a new mini-LED 12.9-inch display, as well as redesigned 24-inch iMac models. Both iPad models and iMacs will be available to pre-order from the April 30, and while Apple said they'll be shipping in the second half of May, it hasn't provided a specific date. Today, however, U.K. retailer and long-time Apple...
Apple Introduces Next-Generation iPad Pro With M1 Chip, Thunderbolt, 5G, XDR Display, and More
Tuesday April 20, 2021 10:40 am PDT by Joe Rossignol
Apple today announced the next-generation iPad Pro with the same M1 chip found in the latest Macs, Thunderbolt and USB4 support, 5G connectivity on cellular models with mmWave support in the United States, and more. With an 8-core CPU and 8-core GPU, Apple says the M1 chip in the new iPad Pro provides up to 50% faster performance and up to 40% faster graphics compared to the A12Z Bionic chip ...

redpajama_set_name: RedPajamaCommonCrawl


Zach Shafer made his New Year's resolution six days late, by the time many others' resolutions had already slipped through the cracks. Despite the late start, he hasn't slowed down in the almost seven months in between.
Shafer, 26, began the year weighing 396 pounds. He worked at the Lyon County Jail but dreamed of being a law enforcement officer. His weight was holding him back. As 2011 began, he realized he had run out of excuses and set out to lose weight to get healthier and realize his career aspirations. As July comes to a close, he's lost more than 120 pounds and has recently become a Lyon County Sheriff's Deputy. He recently said he weighs 270 pounds.
The regimen began by cutting out fried food and red meat. Shafer used to be a whimsical eater, going for fast food based on impulsive cravings. Now, he sets out each week's meals as the week begins. When a craving hits for fast food, it goes unsatisfied. Instead, Shafer eats the food he set out for that time slot. Cheeseburgers, which he used to eat 3-4 times a week, are now a distant memory.
Shafer still makes a point to eat frequently. He eats six small meals a day now so that his metabolism will be working throughout the day.
Along with the diet regimen, Shafer also joined Genesis Health Club. When he first walked in it was an uncomfortable experience. Prior to beginning his weight-loss regimen, Shafer hadn't been engaging in physical activity.
As he began, Shafer would post his latest weights on Facebook, which led to friends and family posting messages of support. That, he said, helped him clear some of the initial hurdles as he established his routine.
Shafer has since found the gym culture to not be so intimidating. When he wants to try a new exercise but isn't sure how, others have been quick to show him. As he's become acquainted with other gym-goers, they've also made sure to keep him on track. When he misses a day, he usually hears about it. As he continues to maintain his seven-day-a-week exercise plan, he's still hoping to lose more weight, with a target weight of 230 pounds.
He's also taken up bicycling. His parents always enjoyed going on bike rides, though he didn't take it up until this year. Now, he's hooked. He bought a bicycle and began by going on five- or six-mile rides. He's since lengthened his trips. He went on a 32-mile ride as a portion of the Dirty Kanza. He rode 30 miles for Olpe Downhome Days. More frequently, he'll meet up with friends to go on 20-mile bike rides.
As he's lost more weight, more activities have become available to him. He enjoys running, and has also begun participating in a spinning class.
"Being 386 pounds is really hard on the knees to run, you just don't feel good," he said. "As soon as the weight started coming off, I think after about the first 50 pounds, I hopped on the treadmill and put it onto 6 and started running. That was a huge milestone for me to be able to do that.
Shafer has been a deputy for about a month. His first assignment has been working security at the Lyon County Courthouse. Soon, he will leave for 14 weeks of training in Hutchinson. He admits not knowing what to expect when he gets there, though he's confident he can maintain his diet and exercise regimen no matter what is thrown at him.
Here's an interesting study on the effects of posting the calorie counts on fast food menu items. Perhaps this should be done universally!
In New York City, there has been a regulation requiring fast-food restaurants to post calorie counts of their menu items. According to a study published today in the British Medical Journal, the listings are affecting consumer choices.
While overall calorie consumption for the thousands of people tracked did not change, customers of McDonald's, Au Bon Pain and KFC were shown to make significant modifications, according to the study funded by the City of New York and the Robert Wood Johnson Foundation.
Advocates of the law wanted to see Americans lose weight, as more than two-thirds of the country's citizens are overweight or obese, conditions linked to health problems like high blood pressure and diabetes.
"We think, overall, these initial findings are positive," Dr. Lynn Silver, director of New York City's Office of Science and Policy and co-author of the report, told Reuters.
The British Medical Journal's website reported that researchers surveyed more than 7,000 people in 2007 and another 8,500 in 2009 at 168 locations covering 11 of the top food chains in the city, BBC News reports.
Fifteen percent reported using the labels and these customers purchased 106 fewer calories than customers who did not use or see them.
Overall, however, there was no significant change in average calorie consumption before and after as some people were consuming more calories in 2009. Subway, the popular sandwich chain, saw a significant increase during the survey because of its promotional offer for a $5, foot-long sandwich. The other chains saw little change in their customers' purchases.
Researchers said it was important if the scheme was going to be more of a success that education campaigns be set up to improve awareness.
While New York City was the focus of this particular study, health experts across the country are keeping a close eye on the results. President Obama's 2010 healthcare overhaul mandates a similar requirement nationwide in an effort to curb the US obesity epidemic.
In 2009, the Centers for Disease Control and Prevention estimated that at least 20 percent of adults in all states, except Colorado, were obese. The CDC also said medical costs related to obesity were estimated to be as high as $147 billion in 2008.
Here's an inspiring article about a 50 year old man that decided to turn his life around and get into shape. If he can do it, so can anyone!
Health problems were ruining his life. Sleep apnea, high blood pressure, obesity — everything seemed to be spiraling out of control.
So Percherke decided he had to make some changes in his life.
Change No. 1 was attending Weight Watchers meetings, getting on the program with the well-known weight-loss company. When he began the diet, Percherke weighed more than 300 pounds. He lost 100.
With his goals of shedding the weight and getting into better health secure, Percherke now can focus on one of his lifelong goals: to compete in the Boston Marathon.
Percherke's remarkable turnaround also has put him into the category of late-40, early 50-somethings who compete in triathlons.
Once he was able to get some of the weight off, about 110 pounds, Percherke set some other goals for himself.
Percherke then decided to go for a 10K, then a half-marathon, then finally a marathon.
"After that, I did a couple of more marathons. Then in spring I heard about the triathlon training, and I thought I always wanted to try something like that," Percherke said.
His brother had done triathlons before, so after signing up at the West Shore YMCA with Kera Daily's YTri training class, Percherke did his first triathlon on June 11.
Bigger stuff being the Boston Marathon.
"I'm not a real fast runner; [it] turns out in a triathlon biking is my strongest point, actually. The goal is now to keep the weight off. I can gain the weight back. It's in my DNA to gain it back," Percherke said.
Percherke is training for the Boiling Springs triathlon, held in August. He would like to work up to a longer, Olympic-distance triathlon.
Some have described his health turnaround as an inspiration. To see photos of Percherke now, you'd never know he had weight problems. Looking fit, like he's done triathlons for years, the 50-year-old, who is between jobs, has a renewed outlook on everything.
It's almost as if he's been born again.
"It's kind of a miracle," Percherke said. "Every day was miserable. I didn't like how I felt. It was always a burden. Walking down an aisle in an office place, you feel big. You feel like you're going to bump into somebody. Maybe people like being heavy. I never liked it. I didn't know how to get rid of it.
Percherke also ran into the problem of not being able to help someone in need. A co-worker was in need of a bone-marrow transplant, and Percherke went to sign up to donate but was told he was too heavy to do so even if he was a perfect match.
"Several little things happened. I always said if I ever lost it, I would do things different. I would change everything," Percherke said.
The first time he set out to compete in a 5K event, Percherke set small goals for himself.
"The goal was to break 30 minutes, and I think I broke it by four seconds. I felt great. It felt like you knew at that point you could do it," Percherke said.
When he felt like he could obtain that goal and did, he moved to the 10K and eventually, as a member of the West Shore YMCA, saw the advertisement for Daily's triathlon class, signed up and has been hooked since.
Percherke describes the feeling running, swimming and biking through some of the towns he's competed in as like that of a rock star, with people he doesn't even know, who don't even know his story, cheering him on to finish.
Percherke had no idea what to expect during his first triathlon. He adopted the brick method of training, where he would take a swim, then go for a bike ride, or do a bike ride then go for a run.
"But you never do all three in training," he said. "What I found out during my first triathlon is that I wasn't a very good [open-water] swimmer. I will admit to being very afraid of the water.
"What I realized was how different lap swimming in a pool is to open water. There's definite fear. I was out on my back float just trying to catch my breath. You can quit if you want to quit, but you think about the people who came to watch you that day, and I thought, I don't want to be the one who doesn't finish this thing," Percherke said.
Percherke also has adopted the idea that 50 is the new 40 or, perhaps in his case, the new 30.
"I don't know if I was ever this healthy. I was large in high school, not 300 pounds, but I was a big guy. I don't know if I was ever in this shape. I think for a lot of us, maybe what it is, coming to grips with we're past the halfway point of our lives and what's left for us out there.


I'm gone to convey my little brother, that he should also visit this website on regular basis to take updated from latest gossip.
It's amazing to pay a quick visit this site and reading the views of all mates regarding this paragraph, while I am also zealous of getting know-how.
Good post. I learn something new and challenging on blogs I stumbleupon on a daily basis. It's always useful to read content from other writers and practice something from their web sites.


text:
IRON MAIDEN Announces May 2020 Australian Tour With KILLSWITCH ENGAGE
British heavy metal legends IRON MAIDEN will embark on the Australian leg of the "Legacy Of The Beast" tour in May 2020. Support on the trek will come from KILLSWITCH ENGAGE.
MAIDEN frontman Bruce Dickinson commented: "We're immensely proud of this show and we've had great reactions from the many fans who came to see us in Europe, North America, Mexico and South America.
"The production for Australia is exactly the same as the other shows on this tour so far and is based on our mobile game the 'Legacy Of The Beast', which basically takes various incarnations of Eddie into many different MAIDEN worlds. This inspired us to put together a stage show to take our fans through different worlds and experiences set to appropriate songs.
"It is not that easy designing different worlds on stage and we put a huge amount of work into this to make it work, and the end result we feel is our most spectacular and certainly the most complex show to date. We've got all kinds of crazy things going on, including a replica Spitfire plane dominating the stage during 'Aces High', tons of pyro, a giant Icarus, muskets, claymores and some truly marvellous flame-throwers which I have a hell of a lot of fun with, as you will see! And of course, we have Eddie, as you've never seen him before, and absolutely loads of other surprises.
"I've had the time of my life playing with all these magnificent props on stage; it's been fantastic. We can't wait to bring this show to you!"
Tickets go on sale on Thursday, November 14 at 12 noon from Ticketek.
May 01 - Perth RAC Arena
May 03 - Adelaide Entertainment Centre
May 05 - Brisbane Entertainment Centre
May 07 - Sydney Qudos Bank Arena
May 11 - Melbourne Rod Laver Arena
MAIDEN's 2019 North, South and Central America trek comprised 44 shows in six countries, which, combined with the band's 2018 European dates, means that the group has taken the "Legacy Of The Beast" show to over one and three quarter of a million fans around the globe.
The first leg of the "Legacy Of The Beast" tour opened in Europe last year to outstanding critical acclaim, not just by the 750,000-plus fans who came to see the show but right across national press and rock media, including The Times (U.K.) newspaper calling it "an extraordinary show filled with world class theatrics… a masterclass in performance and staging."
TIMES OF GRACE To Release Long-Awaited Second Album In The Spring
SKILLET's JOHN COOPER: 'Why I Love Telling People About Jesus'
OZZY OSBOURNE Bassist ROB 'BLASKO' NICHOLSON Joins RIPPLE MUSIC As Executive VP And A&R Of Special Projects
MEGADETH's DAVE MUSTAINE Earns Jiu-Jitsu Purple Belt At 59 Years Old
Here Is How JON SCHAFFER's Arrest Was Covered By TV Stations In His Home State Of Indiana
STASS
Songs Of Flesh And Decay


text:
Alchemy Communities
Benefits in Unlikely Substances.
Benefits Of Ketamine Therapy
Post author By alchemy
Categories In Ketamine
While self-medication is nothing but fire-playing, ketamine has now been recognized as a possible remedy for depression. Users have also been on the rise as well as adulterated drugs claiming to be pure. Always test your substances so that you don't get adverse reactions. As per a recent research published on April 18, 2018 in the American Journal of Psychiatry (AJP), a ketamine-containing nasal spray may relieve depressed symptoms and suicidal thoughts. The research was double-blind in which experimental medication and esketamine (part of ketamine) intranasal combination were contrasted with standard treatment and placebo in order to determine the most common therapy for severe depression in people at high risk of suicide.
Researchers from the Yale School of Medicine, New Haven, Conn., and Janssen Research and Development, and Janssen Medical Affairs, Titusville, N.J., and San Diego, carried out the report. The participants consisted of 68 persons who were randomly allocated for a cumulative period of four weeks to obtain either the intranasal formulation or placebo two days a week. All the participants were offered a normal antidepressant medication during the period of the research. The suicidal ideation was assessed on the basis of patient and clinician viewpoints.
Many drugs require at least four to six weeks to demonstrate their results and the gap may be bridged by utilizing the esketamine spray owing to its immediate effectiveness on anxious patients and others with elevated suicidal tendency. This was a phase-two test, and it will undergo phase-three review, as per the scientists, before obtaining clearance from the Food and Drugs Administration (FDA). Usage of ketamine comes with a warning however.
Possible misuse of ketamine Notwithstanding the capacity advantage of ketamine treatment, the writers have cautioned of the potential for violence. To relieve their misery, often individuals coping with the stress of mental health disorders fall into drug misuse. They may become reliant or addicted after long-term use of any substance. The disease is recognized as co-occurring conditions or dual diagnosis where an patient is struggling from both mental health and drug misuse problems. Management of co-occurring diseases needs to take all the symptoms into consideration and manage them together with improved success.
Alongside the post, the AJP publisher, Robert Freedman, and additional board members have released an editorial. After reviewing documented accounts of prescription opioid misuse, the analysts acknowledged the misuse capacity of ketamine. During the phase-three experiment, they highlighted the need for more work in this area, such as exploring cravings and possible usage of ketamine from other outlets.
Dealing with co-occurring conditions Since ketamine is not yet licensed for care, despite having positive effects in may depressive symptoms and suicidal thoughts. However, a number of people misuse the substance in an effort to self-medicate, relieve discomfort and promote relaxation. Ketamine distorts vision and auditory sensations, which induces hallucinations. It is a common party substance frequently exploited by teenagers and young adults. It is a drug in Schedule III and is used as an anesthetic only. Educate yourself and learn more about using testing kits to help save lives.
Ketamine Administration Providers Organizations (MSOs)
There has been an increase in ketamine users recently. No wonder, because the drug is gaining momentum with its off-label infusion applications for a number of serious illnesses, including depression and mood disorders. However, there has also been a lot of illicit substances claiming to be pure ketamine. You should test your stash with a testing kit to make sure the ketamine is pure. Educate yourself and learn more about the safety of drug implementation. We also have multiple M&A deals related to ketamine clinics and the management companies that serve them. While medical research and business interest in ketamine persists, any doctor or investor wishing to participate in or benefit from such ketamine infusion clinics must become familiar with (1) (and quickly) what is required to prescribe ketamine to store and administer and 2) the myriad laws and regulations relating to medical business practice and business start-ups that may violate them.
Ketamine Infusion Treatments
In California, medical business practice is a very serious business (see sections 2052 and 2400 of the Business & Professions Code). California actually requires stricter compliance than the Feds when it comes to the practice of medical doctrine and anti-kickback, fee sharing, and self-referral laws and regulations. This means that not everyone can perform or manage ketamine infusion treatments here. In California, such treatments must be performed by licensed doctors (although other licensed healthcare providers, such as nurses, may be able to help with these treatments). And these doctors cannot form any business unit with which they can do business – they must band together as a professional medical company (at least 51% must be owned by licensed doctors, while the remaining 49% must be owned by other licensed / registered doctors may be healthcare providers). In addition, physicians must have complete control over the professional medical company and its clinical business and management decisions. This includes how patients are treated and managed, including their patient records and how often a patient is seen.
Then how does a third venture with doctors about ketamine infusion treatments? The answer is very careful. Name the structure of the Management Services Organization (MSO) as a prime example.
MSOs are nothing new when it comes to how non-medical third parties, in addition to medical practice groups, can legally conduct non-clinical administrative business in addition to medical practices through management service contracts. And often, these practice groups rightly need MSOs to manage their practices and grow their business by taking care of certain facilities, administrative, advertising and personnel logistics on behalf of the documents. Because California is so aggressive about medical bar business, MSOs really need to watch this in two main areas when it comes to interacting with doctors (and ketamine infusions are no exception).
According to California's medical corporate practice, it is very clear that MSOs (or non-physicians) do not own, invest in, or control professional medical companies / groups of doctors directly or indirectly. The greatest danger here is in the "control" area, where certain non-clinical management services that can be provided to doctors by the MSO can limit illegal control.
Control will be an evidence-based investigation and the content of the MSO agreement is therefore extremely important. The Board of Trustees of the California Medical Association (1994 and 2010) adopted guidelines instructing doctors what business / practice decisions should be made by doctors, as opposed to business decisions or actions that can be shared between doctors and non-doctors -physicist.
As part of an MSO, decision making falls into three basic categories:
"Exclusive" – "Doctor or layperson is solely responsible for the decision. Neither party is obliged to consult informally with the other."
"Advisor" – "Doctor or layperson is encouraged to informally obtain or receive information or advice from the other, but everyone retains the ultimate decision-making authority."
"Split" – "As a prerequisite for the final action, the doctor or layperson gives a recommendation to the other through a formal process. While the ultimate decision-making authority rests with the party who receives the recommendation, the recommendation is admissible given the importance of the concern entitled to a careful examination. "
The most important decisions that are made exclusively by doctors, among other things, are, for example, the establishment of guidelines for the pure medical practice and the inclusion in the patient files. For the MSO, her decision-making skills may include the selection of administrative personnel, the provision of equipment and the provision of the clinic room (among others).
Compensation for the MSO cannot simply be what the parties decide under the MSO agreement. In California according to Business and Professions Code 650,
". . . the offer, delivery, receipt or acceptance by a person licensed under this department. . . of discounts, reimbursements, commissions, preferences, cartridge dividends, discounts or other consideration, whether in the form of money or otherwise, as compensation or incentive for referring patients, customers or customers to a person, regardless of a company membership Interest or co-ownership in or with a person to whom these patients, customers or customers are referred is illegal. . . . Paying or receiving consideration for services other than patient referral based on a percentage of gross sales or a similar contractual arrangement is not unlawful if the consideration corresponds to the value of the services provided or the reasonable rent, value of premises or Devices that the recipient has rented or made available to the payer. "
The remuneration paid to the MSO can only apply to administrative services provided and can (in some cases) represent a percentage of gross profit, but must reflect the actual market value of the services / equipment / facilities provided. Whether an MSO has a problem with fee sharing is another fact-based investigation that is entirely dependent on the content of the MSO agreement and the practice of the parties. That said, using profit sharing could immediately set red flags on California regulators no matter what.
The main revenue factor of the MSO is the service fees that it charges physicians – usually, and not directly to patients, to avoid the appearance of unlawful fee sharing or too much control – in return for management services. This means that the MSO agreement between the MSO and the doctors is crucial and the MSO generally wants a longer term with few termination rights.
Ketamine infusions here increase the commitment for MSOs (and doctors), where the off-label administration of ketamine is a kind of wild west situation (see here), and the MSO has to comply with the outpatient regulations Health and safety regulations for these special treatments rely heavily on doctors. If doctors fail to treat patients with ketamine infusions in a compliant and responsible manner, doctors are at high risk of civil claims, fines, and penalties (including loss of license to practice). Even criminal prosecution is possible for doctors and also for the MSO as a participant or supporter (or helper / advocate) of this behavior.
Without a doubt, an MSO setup with doctors around ketamine infusions can be incredibly successful. Incorrect structuring can also be a complete regulatory and legal catastrophe for both sides in several ways. It is important to understand the requirements and structure the relationship correctly from the start.
© 2023 Alchemy Communities


text:
Q: running processes step by step
*

*I need to install mysql in my system in the first step

*After installing or modifying the mysql in the system , I need to the run the data base scripts.
The problem here is db scripts started running before mysql setup completes.
I have tried different ways.. using auto run methods...using processes etc
can anybody tell me how to capture the (child)process id which is invoked by the current process(parent). Here in my case parent is invoking child process and exiting.

A: System.Diagnostics.Process has a method WaitForExit.
Edit: To also watch for subprocesses, you can use Win32 Job objects. If you create a process in a job, all of its child processes will also belong to the job (unless someone explicitly detaches them). You can monitor the job for events such as process creation and termination. There is a C# wrapper for job objects, JobObjectWrapper.

redpajama_set_name: RedPajamaStackExchange


Power steering return pipe is located between the steering gear and rubber hose reaching to the cooler power steering fluid.
Return cable support fit into Ford Transit MK7 with rear-wheel drive, the version with of the power steering fluid cooler . The tube power steering is a new product, occurring as a replacement.


Panda Bear has a video for "Crosswords", off this year's Crosswords EP. Directed by Mount Emult, the clip features a gentleman busting a move while trippy visuals play out in the background, on his garments, and on his own body. Check it out below.


text:
Embolism and thrombosis
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Technology appraisal guidance [TA354] Published date: 26 August 2015
2 The technology
3 The company's submission
4 Consideration of the evidence
6 Review of guidance
7 Appraisal Committee members, guideline representatives and NICE project team
8 Sources of evidence considered by the Committee
About this guidance
Clinical effectiveness
Summary of Appraisal Committee's key conclusions
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of edoxaban, having considered evidence on the nature of venous thromboembolism (VTE) and the value placed on the benefits of edoxaban by people with the condition, those who represent them, and clinical experts. It also took into account the effective use of NHS resources.
4.1 The Committee considered the experience of people with VTE. It noted submissions from clinical and patient experts which stated that the impact of a deep vein thrombosis (DVT) or pulmonary embolism (PE) can be devastating, with patients often hospitalised, restricted in movement and unable to continue with previous activities. When recovering from VTE, patients may need further treatment and monitoring. It heard from the patient and clinical experts that the need for International Normalised Ratio (INR) checks when taking warfarin represents a major disadvantage, and the most important issue for patients is to have an effective treatment which minimises disruption to their day‑to‑day lives. The Committee was aware that various models of provision of INR monitoring are in use in England. It heard from the patient experts that some people taking warfarin monitor their own INR levels, but in some areas in the UK this was being made more difficult or phased out. The Committee heard that patients value newer oral anticoagulants such as edoxaban which do not need routine monitoring. In addition, the Committee noted that warfarin has many drug and food interactions which is not the case for the newer agents. The Committee heard from the patient and clinical experts that in the absence of regular monitoring, compliance with the newer anticoagulants would not be regularly checked, and good patient information was vital to help encourage compliance. However, they noted that this was not an issue for most patients, who were well aware of the importance of anticoagulation treatment. The Committee noted that edoxaban has a simple once‑daily dosage, and would usually only need 1 annual monitoring visit to check renal function. The Committee concluded that patients value newer oral anticoagulants such as edoxaban, which cause less disruption to their lives than warfarin.
4.2 The Committee considered the current treatment for people with VTE. It heard from the patient experts that there was variation in practice in the UK. Patients were sometimes not informed about the range of anticoagulants available, and prescription of newer oral anticoagulants depended on local clinical leadership and policies. One expert stated that some clinicians consider it easier to reverse the effects of warfarin than the newer oral anticoagulants, and in some instances warned their patients about the lack of reversibility of newer agents. However, this concern was not necessarily justified because most of the newer anticoagulants can be reversed with prothrombin complex concentrates, and more specific reversing agents are awaiting marketing authorisation. The clinical and patient experts also stated that some hospitals restrict the choice of anticoagulants to minimise prescribing errors, and that rivaroxaban was currently the most widely used of the new oral anticoagulants. The clinical expert noted that there had been a recent drive to increase outpatient treatment for VTE and agents that do not need heparin to be given for a few days at the beginning of treatment would be preferable for the 30% to 40% of patients treated for VTE as an outpatient. However, the clinical expert noted that a large proportion of treatment for VTE is still started as an inpatient, when patients typically have parenteral heparin for several days. In this situation a drug such as edoxaban may be useful because of its simple dosing schedule. The Committee also heard from the clinical expert that having the option to use a lower dose of edoxaban was of value, and the availability of a range of anticoagulant agents was necessary because patients may be allergic to 1 or more agents. The Committee concluded that the choice of anticoagulant treatment would largely depend on the healthcare setting and local policies.
4.3 The Committee considered the Hokusai‑VTE trial. It noted that it had an unconventional design in a number of ways; for example, patients could change dosage during the trial, there was a flexible treatment duration, and the primary efficacy outcome was measured at 12 months irrespective of the time when treatment stopped (which could have been as early as 3 months). The Committee noted that the trial therefore differed from VTE trials for other anticoagulants. The clinical expert agreed that it was unusual that the primary outcome was measured in patients who had potentially been untreated for up to 9 months (although the Committee noted that 60% of patients in the trial had treatment for at least 6 months). However, the company stated that this approach accurately reflected real‑world clinical practice, and led to a more conservative estimate of efficacy, with which the clinical expert agreed. The Committee was aware that the design of the trial was not strictly comparable with other recent trials for newer anticoagulants, and that the value of assessing efficacy several months after some patients had stopped treatment was questionable. However, the trial did allow a choice of dosage, and did not predetermine the length of treatment at the start, both of which mirrored clinical practice. The Committee concluded that Hokusai‑VTE was well designed and suitable for evaluating the clinical effectiveness of edoxaban.
4.4 The Committee considered the baseline characteristics of the patients in the trial. It noted the ERG's concerns about generalisability (section 3.14). However, it heard from the clinical and patient experts that they had no concerns about the generalisability of the trial, including the age of participants, with 1 expert explaining that people can experience VTE at any age. The Committee also noted that the patient population was comparable to that in other trials for newer anticoagulants. The Committee concluded that the results of the clinical trial were generalisable to people with VTE in the NHS and were appropriate for decision making on the clinical effectiveness of edoxaban.
4.5 The Committee discussed the clinical efficacy results from Hokusai‑VTE. It noted that the trial had shown a higher rate of VTE recurrence in the edoxaban group compared with warfarin in the first 30 days, but agreed that caution was needed in interpreting this difference because the numbers were small and the difference was not statistically significant. The Committee concluded that overall the trial had demonstrated that edoxaban was statistically non‑inferior to warfarin for VTE recurrence.
4.6 The Committee considered the network meta‑analysis presented by the company. The Committee noted the wide credible intervals and the non‑inferiority design of the trials in the network. It further noted that the unconventional design of Hokusai‑VTE compared with the other trials in the network had led to heterogeneity. The Committee concluded that no clear differences between treatments for any outcome had been demonstrated, but that the comparative evidence was weak (because of the lack of direct evidence comparing the newer anticoagulants, and the issues noted with the network meta‑analysis) and therefore the results needed to be interpreted with caution.
4.7 The Committee noted that a small number of people with cancer had been included in the trial but that no subgroup analysis results had been presented for these patients. The Committee heard from the clinical expert that the standard treatment for VTE in people with cancer is low‑molecular‑weight heparin. Hokusai‑VTE did not include this as a comparator group, so there was no comparison of edoxaban with the current standard of care for these patients. The Committee concluded that the trial did not provide relevant data for people with cancer who experienced VTE, and it was unable to make any specific recommendation for this subgroup of patients.
4.8 The Committee discussed the adverse events associated with edoxaban. It noted that there were 18 primary intracranial haemorrhages in the warfarin group (of which 6 were fatal) and 5 in the edoxaban group, none of which were fatal (section 3.9). The Committee was aware that intracranial haemorrhage is considered to be the single most serious complication of anticoagulation treatment. It heard from the clinical expert that the reduced risk of intracranial haemorrhage is recognised as a benefit of newer oral anticoagulants in general and there is also the suggestion that, when intracranial haemorrhage does occur, the bleed may be less extensive than with warfarin. However, this benefit needs to be balanced against an increased risk of gastrointestinal bleeding as suggested in the trial; there were 9 more gastrointestinal bleeds in the edoxaban group than in the warfarin group (section 3.9). The Committee heard concerns from the ERG that although Hokusai‑VTE demonstrated a statistically significant reduction in bleeding (major and clinically relevant non‑major bleeding), the reduction for major bleeding alone was not statistically significant. The Committee concluded that there was no statistically significant difference for major bleeding for edoxaban compared with warfarin, but that a reduction in intracranial haemorrhage with edoxaban was a potential substantial benefit.
4.9 The Committee considered the structure of the company's health economic model and the assumptions used. The ERG had raised a number of parameter and structural concerns about the model. The Committee generally agreed with these concerns, particularly:
The assumption that some adverse events such as chronic thromboembolic pulmonary hypertension and post‑thrombotic syndrome were treatment‑related rather than disease‑related.
The exclusion of treatment‑switching after VTE recurrence (the Committee heard from the clinical expert that returning to a treatment that had failed to prevent recurrence was not clinically plausible).
The inclusion of both ischaemic and haemorrhagic stroke within the stroke health state. Ischaemic stroke is not treatment‑related whereas intracranial haemorrhage is; putting them together was an oversimplification and not clinically plausible. It also resulted in potential double‑counting of intracranial haemorrhage because this was also included in the major bleeding health state.
Despite these and other concerns about the reliability of the model, the Committee heard from the ERG that flaws in the model, although important methodologically, did not have a substantial impact on the cost‑effectiveness results, because they affected both arms equally, or because the probabilities of the associated adverse events were low. The Committee concluded that some of the assumptions in the model and model structure lacked clinical plausibility but, taking into account the ERG's comments and analyses, these flaws were not key drivers of cost‑effectiveness.
4.10 The Committee considered the clinical‑effectiveness estimates that had been used in the company's economic model, noting that the estimates were from a network meta‑analysis which had limited capacity to demonstrate statistically significant differences between treatments. The Committee concluded that the efficacy data from the network meta‑analysis contributed to uncertainty in the cost effectiveness results.
4.11 The Committee considered the warfarin monitoring‑cost assumptions used in the company model. The Committee noted that the company had assumed an annual cost of warfarin monitoring of approximately £630. The Committee discussed whether this cost was reasonable. It heard from the ERG that according to their clinical experts the company had overestimated the costs of monitoring – the frequency was too high, and the monitoring would usually be done by a nurse rather than a consultant as assumed in the company base case. After reducing the frequency of visits and assuming monitoring would be nurse‑led, the ERG had used a monitoring cost of £342 in the first year and £190 after that. The Committee heard from the company that it had access to unpublished preliminary registry data suggesting that monitoring costs in clinical practice were substantially higher than the estimates used by the ERG. The Committee was aware that there is considerable variation in how warfarin monitoring is provided in the NHS, which would affect the costs, and that there is also individual variation (some patients have INR levels which are more unstable than others and need more frequent monitoring). The exact frequency and cost of warfarin monitoring is therefore unknown. The Committee referred to previous appraisals in its consideration of the very different estimates from the company and ERG. It noted that the cost assumed by the company was substantially higher than the range considered plausible in previous appraisals for VTE (£304 to £379). The Committee concluded that the company estimates were higher than had previously been accepted as plausible and the ERG estimates for the first year were closer to those previously accepted. However, the precise costs of warfarin monitoring remained uncertain.
4.12 The Committee considered the cost‑effectiveness estimates generated by the company and ERG. It noted that the warfarin monitoring cost was the main driver of the cost‑effectiveness estimates. The Committee agreed that the cost of monitoring in the first year in the ERG base case was more consistent with previous appraisals than the company's estimate. Therefore, it considered that the ICER relative to warfarin was likely to be closer to the ERG estimate of £26,000 per QALY gained than the company estimate of approximately £2500 per QALY gained. Nevertheless, it considered that both ICERs were subject to high levels of uncertainty because of the previously discussed flaws in the company model on which they were based, and the lack of definitive warfarin monitoring costs in the NHS. Noting these uncertainties, the Committee further considered the cost effectiveness of edoxaban compared with other anticoagulants that had been considered in previous appraisals for the treatment of VTE. The Committee accepted that the clinical effectiveness of edoxaban had been adequately demonstrated by the clinical trial. It also noted that the price of edoxaban was similar to one of the other agents, rivaroxaban. Taking into account the lack of any clear trial evidence that edoxaban was substantially different from the other newer oral anticoagulants, and the testimony of the experts, the Committee concluded that the most plausible ICER was likely to be in line with that of the other oral anticoagulants already recommended in previous NICE guidance for the treatment of VTE. The Committee therefore concluded that edoxaban could be recommended as a cost‑effective use of NHS resources.
4.13 The Committee considered whether it should take into account the consequences of the Pharmaceutical Price Regulation Scheme (PPRS) 2014, and in particular the PPRS Payment Mechanism, when appraising edoxaban. The Committee noted NICE's position statement in this regard, and accepted the conclusion 'that the 2014 PPRS Payment Mechanism should not, as a matter of course, be regarded as a relevant consideration in its assessment of the cost effectiveness of branded medicines'. The Committee heard nothing to suggest that there is any basis for taking a different view with regard to the relevance of the PPRS to this appraisal of edoxaban. It therefore concluded that the PPRS Payment Mechanism was not relevant for its consideration of the cost effectiveness of edoxaban.
Key conclusion
Edoxaban is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.
Taking into account the similar price of edoxaban to rivaroxaban, the lack of any clear trial evidence that edoxaban was substantially different from the other newer oral anticoagulants, and the testimony of the experts, the Committee concluded that the most plausible ICER was likely to be in line with that of the other oral anticoagulants already recommended in previous NICE guidance for the treatment of VTE. The Committee therefore concluded that edoxaban could be recommended as a cost‑effective use of NHS resources.
1.1, 4.12
Clinical need of patients, including the availability of alternative treatments
The Committee noted that the impact of a DVT or PE can be devastating, with patients often hospitalised, restricted in movement and unable to continue with previous activities. It heard from the patient and clinical experts that the need for International Normalised Ratio (INR) checks when taking warfarin represents a major disadvantage. The Committee noted that edoxaban has a simple once‑daily dosage, and would usually only need 1 annual monitoring visit to check renal function. The Committee concluded that patients value newer oral anticoagulants such as edoxaban, which cause less disruption to their lives than warfarin.
Proposed benefits of the technology
How innovative is the technology in its potential to make a significant and substantial impact on health‑related benefits?
The Committee noted that edoxaban has a simple once‑daily dosage, and would usually only need 1 annual monitoring visit to check renal function.
What is the position of the treatment in the pathway of care for the condition?
The Committee heard from the clinical and patient experts that some hospital protocols limit the choice of anticoagulants to minimise prescribing errors. It heard from the clinical expert that agents that do not need heparin would be preferable for the 30% to 40% of patients treated for VTE as an outpatient. However, those treated for VTE as an inpatient typically have parenteral heparin for several days, and in this situation a drug such as edoxaban may be preferable, because of its simple dosing schedule. A range of anticoagulant agents is necessary because patients may be allergic to 1 or more agents. The Committee concluded that the choice of anticoagulant treatment would largely depend on the healthcare setting and local policies.
The Committee noted that there were fewer primary intracranial haemorrhages in the edoxaban group of the trial compared with the warfarin group. It heard from the clinical expert that this was recognised as a benefit of newer oral anticoagulants in general, but that this benefit needs to be balanced against an increased risk of gastrointestinal bleeding with the newer oral anticoagulants.
The Committee concluded that there was no statistically significant difference for major bleeding for edoxaban compared with warfarin, but that a reduction in intracranial haemorrhage with edoxaban was a potential substantial benefit.
Evidence for clinical effectiveness
Availability, nature and quality of evidence
The Committee noted that the Hokusai‑VTE trial had an unconventional design; for example, the primary efficacy outcome was measured at 12 months irrespective of the time when treatment stopped. The Committee noted that the design of the trial was not strictly comparable with other recent trials for newer anticoagulants, and that the value of assessing efficacy several months after some patients had stopped treatment was questionable. However, the trial did allow a choice of dosage, and did not predetermine the length of treatment at the start of treatment, both of which mirrored clinical practice. The Committee concluded that Hokusai‑VTE was well designed and suitable for decision making on the clinical effectiveness of edoxaban.
Relevance to general clinical practice in the NHS
The Committee noted the ERG's concerns about the generalisability of Hokusai‑VTE to the UK population. However, it heard from the clinical and patient experts that they had no concerns about the generalisability of the trial. The Committee also noted that the patient population was comparable to that in other trials for newer anticoagulants. The Committee concluded that the results of the trial were generalisable to people with VTE in the NHS and were appropriate for decision making on the clinical effectiveness of edoxaban.
3.14, 4.4
Uncertainties generated by the evidence
The Committee noted the wide credible intervals and the non‑inferiority design of the trials in the network meta‑analysis. It further noted that the unconventional design of Hokusai‑VTE had led to heterogeneity. The Committee concluded that no clear differences between treatments for any outcome had been demonstrated, but that the comparative evidence was weak (because of the lack of direct evidence comparing the newer anticoagulants, and the issues noted with the network meta‑analysis) and therefore the results needed to be interpreted with caution.
Are there any clinically relevant subgroups for which there is evidence of differential effectiveness?
The Committee noted that a small number of people with cancer had been included in the trial but that no subgroup analysis results had been presented for these patients. It heard from the clinical expert that the standard treatment for VTE in people with cancer is low‑molecular‑weight heparin. Hokusai‑VTE did not include this as a comparator arm, so there was no comparison of edoxaban with the current standard of care for these patients. The Committee concluded that the trial did not provide relevant data for people with cancer who experienced VTE.
Estimate of the size of the clinical effectiveness including strength of supporting evidence
The Committee concluded that the trial was well designed, appropriately powered, and had demonstrated that edoxaban was statistically non‑inferior to warfarin for VTE recurrence.
Evidence for cost effectiveness
Availability and nature of evidence
The company developed a new economic model that compared edoxaban with warfarin, rivaroxaban and dabigatran etexilate for the treatment and secondary prevention of an acute VTE event. The model included 12 states representing treatment status (on‑treatment or off‑treatment health states), adverse events, and death. The model had a lifetime time horizon (maximum 50 years) and each model cycle was 2‑weeks long.
Uncertainties around and plausibility of assumptions and inputs in the economic model
The Committee noted that the modelled clinical‑effectiveness estimates were from a network meta‑analysis which had limited capacity to demonstrate statistically significant differences between treatments. The Committee concluded that there was uncertainty about the cost‑effectiveness results.
The Committee noted and agreed with the parameter and structural concerns about the model noted by the ERG, particularly: the assumption that some adverse events were treatment‑related rather than disease‑related; the exclusion of treatment‑switching after VTE recurrence; and the inclusion of both ischaemic and haemorrhagic stroke within the stroke health state. The Committee concluded that some of the assumptions in the model and the model structure lacked clinical plausibility but, taking into account the ERG comments and analyses, these flaws were not key drivers of cost‑effectiveness.
The Committee agreed that the cost‑effectiveness results were largely driven by the estimates of warfarin monitoring costs, and noted that the costs of monitoring assumed by the company were substantially higher than the range considered plausible in previous appraisals for VTE (£304 to £379). The Committee concluded that the ERG estimates for the first year were closer to those previously accepted as plausible. However, the precise costs of warfarin monitoring remained uncertain.
Incorporation of health‑related quality‑of‑life benefits and utility values
Have any potential significant and substantial health‑related benefits been identified that were not included in the economic model, and how have they been considered?
At entry into the model, for the first cycle only, all patients had a utility value that reflected the disutility of the initial VTE (derived from Hokusai‑VTE data). For all subsequent cycles, all patients in all treatment groups were assigned age‑dependent baseline utility values from the general population without illness. When patients experienced adverse events in the model, the company applied a health‑state‑related utility decrement that was deducted from the baseline utility value (derived from its systematic literature review).
Are there specific groups of people for whom the technology is particularly cost effective?
The Committee concluded that the trial did not provide relevant data for people with cancer who experienced VTE, and it was unable to make any specific recommendation for this subgroup of patients.
What are the key drivers of cost effectiveness?
The Committee agreed that the cost‑effectiveness results were largely driven by the estimates of warfarin monitoring costs.
Most likely cost‑effectiveness estimate (given as an ICER)
The Committee agreed that the ICER was likely to be closer to the ERG estimate of £26,000 per QALY gained than the company estimate of approximately £2500 per QALY gained. Nevertheless, it considered that both ICERs were subject to high levels of uncertainty because of parameter and structural uncertainties in the model.
4.11, 4.12
Additional factors taken into account
Patient access schemes (PPRS)
End‑of‑life considerations
Equalities considerations and social value judgements


text:
EPA Cites Newhall Ranch Concerns
by ranch-river | Sep 3, 2009 | News
Plans for the sprawling, Valencia-sized Newhall Ranch community call for filling in too much of the Santa Clara River and its tributaries, the Environmental Protection Agency said.
As part of the development, The Newhall Land and Farming Co. would use dirt to fill in a portion of the river's floodplain, stabilizing it for construction on the roughly 12,000-acre site.
"That fill can destroy or adversely affect water bodies," said David Smith, manager of the EPA's wetlands office in San Francisco.
"The Santa Clara is a very high-priority river. It's an aquatic resource of national importance."
While the fill and stream channels proposed for Newhall Ranch are better than mass concrete lining of riverbed, he said, "they are proposing to fill a lot of area, about 80 acres."
The EPA last month sent a letter to the Army Corps of Engineers detailing its concerns about the project. The letter, dated Aug. 24, was sent to Col. Thomas Magness, district engineer for the Army Corps' Los Angeles District, and signed by Alexis Strauss, director of the water division for the EPA's Pacific Southwest office.
The document cites the presence of 12 federally endangered plant and animal species in the Santa Clara River.
Smith lauded Newhall Land and Farming for its overall plan for the 21,000-home Newhall Ranch but said there are still unresolved issues.
"There's clearly a lot of work left to be done," he said.
Smith said the EPA is also concerned about a perceived a lack of analyses for alternatives to the proposed infill. Also, he questioned how potential effects of the infill will be lessened.
The Santa Clara River is the last river in Southern California to remain unchanneled by concrete, running some 116 miles from the San Gabriel Mountains west through Ventura County to the Pacific Ocean.
The Newhall Ranch Specific Plan was approved in 2003 by the Los Angeles County Regional Planning Commission, and the environmental impact report was compiled over five years at a cost of millions of dollars.
The Army Corps of Engineers and the state Department of Fish and Game are the lead agencies overseeing the EIR.
Newhall Land and Farming Co. spokeswoman Marlee Lauffer has said the developer expects the Army Corps to make its final decision on the report in early 2010.
If the EIR is approved, Newhall Land can begin obtaining the necessary permits required for construction of Newhall Ranch.
The comment period for the draft EIR closed at the end of August, and the Army Corps is reviewing submitted comments, said Jay Field, spokesman for the corps' office in Los Angeles.
A final report will be released within the coming months with the Army Corps' response to public comments.
Newhall Land officials are also reviewing the public comments, Lauffer said.
She said protecting the river was key to the design of Newhall Ranch.
As part of Newhall Ranch's development, 5,700 acres of high country will be set aside as open space. In addition, 970 acres of the Santa Clara River will be protected, and five areas are set aside for protection of the threatened San Fernando Valley spineflower.


Cite this item: Craig E, Reddington A, Wicken A, Oben G, & Simpson J. Child Poverty Monitor 2013 Technical Report (Updated 2014). Dunedin: NZ Child & Youth Epidemiology Service, University of Otago; 2013.
This Technical Report marks a new step in monitoring child poverty and social health indicators in New Zealand. It began with a partnership being established between the Office of the Children's Commissioner, the University of Otago's New Zealand Child and Youth Epidemiology Service (NZCYES) and the J R McKenzie Trust. This partnership saw a gap in publicly-available child poverty measures, and is addressing this gap by compiling, publishing and disseminating annual measurements on child poverty in New Zealand.
This Report provides data and technical information on child poverty measures, economic indicators, and child health measures. It builds on the information in previous Children's Social Health Monitor updates, so that the same data is still compiled and reported consistently. This Technical Report, however, adds new dimensions around child poverty measures.
The child poverty measures included align closely to the recommendation of the EAG to have a suite of measures to capture different aspects of child poverty. We have included measures on income poverty, material hardship, severity and persistence of child poverty. For these elements, we rely heavily on data available in the Ministry of Social Development report Household Incomes in New Zealand: Trends in Indicators of Inequality and Hardship 1982 to 2012.


Scarfox64: Can you concisely explain what exactly happened earlier today?
Scarfox64: So what was your next move?
Scarfox64: Really? At the same time?! That must've been harrowing!
Mr. Jimenez: It was. Luckily, I was able to contact someone working there and they confirmed that the runway was clear. We explained our situation, and they were able to accommodate us. We were incredibly grateful for the assistance.
Scarfox64: What do you two attribute in averting this potential catastrophe?
Mr. Ford: Mr. Jimenez's knowledge of the area was an indisputable advantage.
Mr. Jimenez: As was Mr. Ford's decades of experience in aviation. As well as the Nimbus' Enus engines. I mean, imagine flying a plane with one and a half engines successfully. It's a testament to their power and efficiency.
Scarfox64: Thank you for your time gentlemen.
Mr. Jimenez: Glad to help.
Damn pilots can't fly for jack. I don't trust those Shamals either, always crashin'.
Engine failure incidents are incredibly rare and only three have occurred in the past ten years, the previous one in 2013. Foul play is not suspected in today's events. The aircraft has been grounded until further notice and the engine is currently being inspected to determine the cause of the partial failure.


text:
Share Title: Terence Tao
Terence Tao ( Expand | Collapse )
He received the Salem Prize in 2000, the Bôcher Prize in 2002, and the Clay Research Award in 2003, for his contributions to analysis including work on the Kakeya conjecture and wave maps. In 2005 he received the American Mathematical Society's Levi L. Conant Prize with Allen Knutson, and in 2006 he was awarded the SASTRA Ramanujan Prize.
In 2004, Ben Green and Tao released a preprint proving what is now known as the Green-Tao theorem. This theorem states that there are arbitrarily long arithmetic progressions of prime numbers. The New York Times described it this way:[9][10]
" In 2004, Dr. Tao, along with Ben Green, a mathematician now at the University of Cambridge in England, solved a problem related to the Twin Prime Conjecture by looking at prime number progressions — series of numbers equally spaced. (For example, 3, 7 and 11 constitute a progression of prime numbers with a spacing of 4; the next number in the sequence, 15, is not prime.) Dr. Tao and Dr. Green proved that it is always possible to find, somewhere in the infinity of integers, a progression of prime numbers of equal spacing and any length. "
For this and other work, he was awarded the Australian Mathematical Society Medal.
In 2006, at the 25th International Congress of Mathematicians in Madrid, he became one of the youngest, the first Australian, and the first UCLA faculty member ever to be awarded a Fields Medal. An article by New Scientist[11] writes of his ability:
" Such is Tao's reputation that mathematicians now compete to interest him in their problems, and he is becoming a kind of Mr Fix-it for frustrated researchers. "If you're stuck on a problem, then one way out is to interest Terence Tao," says Fefferman. "
Tao was a finalist to become Australian of the Year in 2007.[12]
Terence Tao Math Prodigy Fields Medal


text:
The politics of environmental destruction
You'd think I'd get tired of this, wouldn't you? Alas, the fight does wear me down, but I must persist.
My good friend and colleague, the legendary Professor Paul Ehrlich of Stanford University, as well as his equally legendary wife, Anne, will be joining us in Adelaide for a brief visit during their annual southern migration.
Apart from just catching up over a few good bottles of wine (oh, do those two enjoy fine wines!), we have the immense privilege of having Paul appear at two events while he's in town.
I'm really only going to be talking about the second of the two events (the first is a Science Meets Parliament gig with me and many others at the South Australia Parliament on 12 November): a grand, public lecture and Q&A session held at Flinders University on Wednesday, 13 November.
Haven't heard of Paul? Where have you been hiding? If by some miracle you haven't, here's a brief bio:
Paul Ehrlich is Bing Professor of Population Studies Emeritus, President of the Center for Conservation Biology, Department of Biology, Stanford University and Adjunct Professor, University of Technology, Sydney. He does research in population biology (includes ecology, evolutionary biology, behavior, and human ecology and cultural evolution). Ehrlich has carried out field, laboratory and theoretical research on a wide array of problems ranging from the dynamics and genetics of insect populations, studies of the ecological and evolutionary interactions of plants and herbivores, and the behavioral ecology of birds and reef fishes, to experimental studies of the effects of crowding on human beings and studies of cultural evolution, especially the evolution of norms. He is President of the Millennium Alliance for Humanity and the Biosphere and is author and coauthor of more than 1100 scientific papers and articles in the popular press and over 40 books. He is best known to his efforts to alert the public to the many intertwined drivers that are pushing humanity toward a collapse of civilization – especially overpopulation, overconsumption by the rich, and lack of economic, racial, and gender equity. Ehrlich is a Fellow of the American Academy of Arts and Sciences, the American Entomological Society and the Beijer Institute of Ecological Economics, and a member of the United States National Academy of Sciences and the American Philosophical Society. He is a Foreign Member of the Royal Society, an Honorary Member of the British Ecological Society and an Honorary Fellow of the Royal Entomological Society. Among his many other honours are the Royal Swedish Academy of Sciences, Crafoord Prize in Population Biology and the Conservation of Biological Diversity (an explicit replacement for the Nobel Prize); a MacArthur Prize Fellowship; the Volvo Environment Prize; UNEP Sasakawa Environment Prize; the Heinz Award for the Environment; the Tyler Prize for Environmental Achievement; the Heineken Prize for Environmental Sciences; the Blue Planet Prize; the Eminent Ecologist award of the Ecological Society of America, the Margalef Prize in Ecology and Environmental Sciences, and the BBVA Frontiers of Knowledge Award in Ecology and Conservation Biology. Prof Ehrlich has appeared as a guest on more than 1000 TV and radio programs; he also was a correspondent for NBC News. He has given many hundreds of public lectures in the past 50 years.
I hope your jaw just dropped.
Tags: Anthropocene, climate change, climate disruption, environment, Flinders University, Paul Ehrlich, politics, public event, public lecture
Categories : anthropocene, Australia, biodiversity, biowealth, celebrity, climate change, conservation, conservation biology, conservation scholars, corruption, decline, deforestation, development, economics, ecosystem, ecosystem services, education, Endarkenment, environmental economics, environmental policy, ethics, exploitation, extinction, extremism, Flinders University, food, governance, habitat loss, health, human overpopulation, impact, investment, media, pollution, poverty, science, science communication, South Australia, sustainability, synergies, threatened species, toxification
10 things I wish I knew before doing an Honours degree
ORIGINALLY PUBLISHED ON THE GE.BLOG
In 2018 I started my Honours degree in biodiversity and conservation at Flinders University. I had completed my Bachelor of Science in 2017, after being accepted in the Honours stream through my Year 12 Australian Tertiary Admission Rank (ATAR).
I will not sugar-coat it — I was a bad Bachelor student. I scarcely attended classes and at times submitted sub-par work. I believed that as long as I didn't fail anything I would still be able to do my Honours, so I did the bare minimum and just got by. However in the last semester I discovered I needed an average GPA of 5.0 to secure my Honours position, regardless of what stream I was doing. Panic ensued, I was already too deep in my final semester of not achieving to pull my grades around. Thankfully, I was eventually accepted, after having to plead my case with the Honours board.
In the end I managed to score myself a First Class Honours and a PhD candidature (and hopefully soon a publication). Honours was definitely a struggle, but it was also one of the best experiences of my life. I just wish I had known these 10 things before I started …
1. You will fail
Not the brightest note to start on, but don't fear, everyone fails. Honours is full of ups and downs, and at some point, somewhere along the line, something in your project will go wrong. But it's okay! It happens to every person that has ever done an Honours or a PhD. Whether the failing is small or catastrophic, remember this happens all the time.
More importantly your supervisor or co-ordinator sees it all the time. The best thing to do is tell your supervisor and your co-ordinator early on. It may be a simple case of steering your research in a slightly new direction, changing the scope of your project, or even taking some extra time. It's okay to fail, just keep pushing. Read the rest of this entry »
Tags: advice, Flinders University, graduate student transition, Honours, student, tips
Categories : research, science, science writing, scientific writing
How to feed the world without costing the Earth
I'm excited to announce the upcoming public lecture by world-renowned sustainability scientist, Professor Andrew Balmford, at Flinders University on 17 July 2018.
Andrew is Professor of Conservation Science and a Royal Society Wolfson Research Merit Award holder at the Department of Zoology, University of Cambridge, and is on sabbatical at University of Tasmania until December 2018. His main research interests are exploring how conservation might best be reconciled with land-demanding activities such as farming, quantifying the costs and benefits of effective conservation, and examining what works in conservation. In his book Wild Hope (Chicago University Press), he argues that cautious optimism is essential in tackling environmental challenges. Andrew helped establish the Student Conference on Conservation Science, and Earth Optimism.
Professor Balmford will be presenting his seminar "How to feed the world without costing the Earth" (hosted by the Ecology & Evolution Research Group) at the Bedford Park Campus of Flinders University in South Lecture Theatre 1, from 12:00-13:00 on 17 July 2018. All are welcome.
Abstract: Globally, agriculture is the greatest threat to biodiversity and a major contributor to anthropogenic greenhouse gas emissions. How we choose to deal with rising human food demand will to a large degree determine the state of biodiversity and the wider environment in the 21st century. Read the rest of this entry »
Tags: Adelaide, agriculture, Andrew Balmford, biodiversity loss, extinction, Flinders University, food, land sharing, land sparing, lecture, presentation, seminar, sustainability, University of Cambridge
Categories : agriculture, biodiversity, conservation, conservation biology, conservation ecology, conservation scholars, food, human overpopulation
Postdoctoral position re-opened in Global Ecology
I believe it is important to clarify a few things about the job advertisement that we are re-opening.
As many of you might recall, we advertised two positions in paleo-ecological modelling back in July — one in ecological networks, and the other in vegetation modelling.
We decided to do something a little unusual with the vegetation modelling position by only accepting applications from women. We did this expressly to increase the probability of attracting excellent women candidates, and to increase the number of women scientists in our lab.
I'm happy to say that we received many great applications for both positions, and whether or not it was related, most of the applicants for both positions were women (83%). As it turned out, we ended up offering the network position to a woman applicant, but we were unable to find an ideal candidate for the vegetation modelling job (i.e., the one that was originally targeting women only).
Our decision not to appoint anyone in the first round of applicants for the vegetation modelling position was clearly not related to the fact that it a woman-only position, mainly because we had so many excellent women candidates for both positions (and ended up hiring a woman for the position that was open to both genders). In other words, it seems to be a just one of those random things.
That said, we are still in need of a great vegetation modeller (or at least, someone who has the capacity to learn this knowledge), and so we have decided to re-open the announcement to both genders. However, it should go without saying that we particularly encourage women to apply.
The full details of the position, essential and desired criteria, and application process are available here (Vacancy Reference Number 17115). Note that the application closing date is 15 November 2017.
Please distribute this widely among your networks.
Tags: ecological modelling, ecology, employment, Flinders University, gender equality, Global Ecology, job, modelling, postdoc, Postdoctoral Fellow, science, scientists, women in science, Women in STEMM
Categories : bottom-up ecology, community ecology, ecology, modelling, palaeo-ecology, vegetation
Two new postdoctoral positions in ecological network & vegetation modelling announced
With the official start of the new ARC Centre of Excellence for Australian Biodiversity and Heritage (CABAH) in July, I am pleased to announce two new CABAH-funded postdoctoral positions (a.k.a. Research Associates) in my global ecology lab at Flinders University in Adelaide (Flinders Modelling Node).
One of these positions is a little different, and represents something of an experiment. The Research Associate in Palaeo-Vegetation Modelling is being restricted to women candidates; in other words, we're only accepting applications from women for this one. In a quest to improve the gender balance in my lab and in universities in general, this is a step in the right direction.
The project itself is not overly prescribed, but we would like something along the following lines of inquiry: Read the rest of this entry »
Tags: CABAH, Centre of Excellence for Australian Biodiversity and Heritage, ecological networks, employment, Flinders University, gender, gender balance, job, jobs, mathematics, modelling, models, postdoctoral fellowship, STEM, vegetation, women in stem, women-only
Categories : Australia, biodiversity, biogeography, bottom-up ecology, climate change, community ecology, conservation, ecology, ecosystem, ecosystem function, extinction, extinction debt, Flinders University, function, genetics, harvest, jobs, mathematics, meso-predator release, minimum viable population, modelling, palaeo-ecology, population dynamics, population viability analysis, predation, predator, top-down ecology
Job: Research Fellow in Palaeo-Ecological Modelling
© seppo.net
I have another postdoctoral fellowship to advertise! All the details you need for applying are below.
KEY PURPOSE
Scientific data such as fossil and archaeological records used as proxy to reconstruct past environments and biological communities (including humans) are sparse, often ambiguous or contradictory when establishing any consensus on timing or routes of initial human arrival and subsequent spread, the timing or extent of major changes in climate and other environmental perturbations, or the timing or regional pattern of biological extinctions.
The Research Fellow (Palaeo-Ecological Modelling) will assist in addressing these problems by developing state-of-the-art analytical and simulation tools to infer regional pattern of both the timing of human colonisation and megafauna extinction based on incomplete and sparse dataset, and investigating past environmental changes and human responses to identify their underlying causes and consequences on Australia's landscapes, biodiversity and cultural history.
ORGANISATIONAL ENVIRONMENT
The position will be based in the School of Biological Sciences in the Faculty of Science & Engineering at Flinders University. Flinders University boasts a world-class Palaeontology Research Group (PRG) and the new Global Ecology Research Laboratory that have close association with the research-intensive South Australian Museum. These research groups contribute to building a dynamic research environment that explores the continuum of environmental and evolutionary research from the ancient to modern molecular ecology and phylogeography. The School of Biological Sciences is an integrated community researching and teaching biology, and has a long history of science innovation. The appointee will join an interdisciplinary school of approximately 45 academic staff. The teaching and research activities of the School are supported by a range of technical and administrative infrastructure services.
The key responsibilities and selection criteria identified for this position should be read in conjunction with the Flinders University Academic Profiles for the relevant academic classification (scroll down to Academic Profiles).
The Research Fellow (Palaeo-Ecological Modelling) will work under the direction of the Project Chief Investigator, and will be required to: Read the rest of this entry »
Tags: Adelaide, ecology, employment, Flinders University, job, modelling, palaeo-ecology, postdoc, Postdoctoral Fellow, science, South Australia
Categories : Australia, climate change, community ecology, conservation, demography, ecology, environmental science, extinction, Flinders University, mammal, minimum viable population, modelling, palaeo-ecology, population dynamics, research, species distribution model
ConservationBytes.com Leaving the University of Adelaide
In reality, ConservationBytes.com isn't going anywhere. But Corey Bradshaw is.
You'll still be able to read the regular posts on ConservationBytes.com without having to change a thing; I'll just be writing them from a different office across the city.
Yes, I'm staying in beautiful Adelaide in South Australia, but my time at the University of Adelaide has come to an end. I'm excited to report that as of 16 January 2017 I'll be occupying the new position of Matthew Flinders Fellow in Global Ecology at Flinders University in the School of Biological Sciences.
I thank my colleagues at the University of Adelaide for the productive time I've had here.
On to bigger and better things.
Tags: Flinders University


As you know, I love me some white, this friends, has been the case for a very VERY long time…however, all good things come to an end and little pops of darkness, here and there are weeding their way into my life.
This is the result of that in the kitchen…the beauty of a handmade timber kitchen, is if the mood takes you, you can pop to the paint shop, talk to the nice Paint Man about finishes, come home and change the look of your kitchen, all before you've made dinner and poured a glass of wine. Excellent.
Looks great! Were your counters always black or did you paint them? I love your floors!
I am in the process now of having a new fitted kitchen in a driftwood finish. It is like a building site at the moment so hope it turns out as nice as this one.
Wow, I love the beautiful white and black contrast. Even your toaster is white!
I have some stunning black and white gloss sideboards, but I'm over here in the UK!


text:
Valve's In-Depth Announcement About Steam Security And Trading
on 10th of December 2015 @ 12:56 am UTC
Christmas truly is a time of miracles because Valve have actually come out and spoken in-depth about an important topic that's been circulating the Steam forums recently, that of account security and trading. To say Valve has little community interaction would be one hell of an understatement so when they do actually talk, it tends to be worth listening to.
In the recent announcement they have confirmed that there is indeed a raise in the number of hacked Steam accounts but they've also detailed all the various options available to them as well as what they're going to do about it moving forward. I'll do a brief overview of the announcement but if you want to read the full version yourself head over here.
First of all, there is some bad news. The number of people who make a business out of stealing Steam accounts has increased significantly and they aren't just targeting new and inexperienced users anymore.
"What used to be a handful of hackers is now a highly effective, organized network, in the business of stealing and selling items. It would be easier for them to go after the users who don't understand how to stay secure online, but the prevalence of items make it worthwhile to target everyone. We see around 77,000 accounts hijacked and pillaged each month.
These are not new or naïve users; these are professional CS:GO players, reddit contributors, item traders, etc. Users can be targeted randomly as part of a larger group or even individually. Hackers can wait months for a payoff, all the while relentlessly attempting to gain access. It's a losing battle to protect your items against someone who steals them for a living."
While this does mean that everyone is theoretically at risk I'd still wager that its those with relatively weak passwords, or bad browsing habits, that are the most affected and that is an area you fortify yourself. Make sure you have different passwords for every single high profile account you use and, this should be obvious, don't install random junk from the Internet and don't clink on suspicious links you get sent through Steam chat because no, it is not actually your brother.
Again, this won't protect you from someone who is both skilled and seriously after your account but in the vast majority of cases it will.
So what Valve has decided to do is to create their own version of a mobile authenticator so even if someone, somehow gets complete control over your Steam account they can't do anything with it because all important changes and trades would need to be confirmed via the authenticator. Which does unfortunately mean that third party authenticators will simply not work with this system.
"We needed to create our own two-factor authenticator because we need to show users the contents of the trade on a separate device and have them confirm it there. Requiring users to take a code from a generic authenticator and enter it into a hijacked PC to confirm a trade meant that hackers could trick them into trading away items they didn't intend to. This basically made it impossible to use a generic third party authenticator, such as Google Authenticator, to confirm trades."
But with every sweeping change there will be issues and in this case that translates to a less than ideal experience for people that either won't or can't use the new authenticator. So with all of that in mind Valve have done a compromise and came to the following system that will be deployed later today:
"- Anyone losing items in a trade will need to have a Steam Guard Mobile Authenticator enabled on their account for at least 7 days and have trade confirmations turned on. Otherwise, items will be held by Steam for up to 3 days before delivery.--
- If you've been friends for at least 1 year, items will be held by Steam for up to 1 day before delivery.
- Accounts with a Mobile Authenticator enabled for at least 7 days are no longer restricted from trading or using the Market when using a new device since trades on the new device will be protected by the Mobile Authenticator.
This means that anyone using the Steam Guard Mobile Authenticator to confirm trades is able to continue trading as always. Users who haven't enabled it, or can't, can still trade, but they'll have to wait up to 3 days for the trade to go through. This gives both Steam and users the time to discover their accounts have been hacked and recover it before the hackers can steal their items."
This system is clearly not perfect, and Valve themselves know it, but if what they say is true (they have no reason to lie about this) and there is a big increase in hacked accounts I really don't see another way of doing things.
It just unfortunate that people with Windows phones that don't have an official Steam app or people without phones altogether will have to bear with significantly slower trading times. Hopefully they'll release physical authenticators, much like how Blizzard did, sometime in the future and solve most of these issues in a single move.


text:
Партенофили́я ( — девственница,  — любовь) — половое влечение к девственницам. Термин введён немецким сексологом Магнусом Хиршфельдом.

Употребительность термина сравнительно невелика — по мнению автора книги Virgin: The Untouched History Ханны Бланк — «у нас так долго не было названия для этой особенности влечения, поскольку оно считалось в нашей культуре полностью нормальным, приемлемым и идеологически корректным». Некоторые специалисты переосмысляют термин как влечение к девушкам, находящимся в процессе полового созревания, — выделяя его, таким образом, из состава нимфофилии (так, например, в книге Франка ван Рее «Педофилия — противоречивый вопрос»). В популярной и бульварной литературе эти два понимания термина смешиваются, так что Збигнев Лев-Старович упоминает «партенофилию (сексуальное влечение к девственницам), являющуюся одним из типов педофилии».

Примечания

Сексуальные предпочтения

redpajama_set_name: RedPajamaWikipedia


Leaning in with your wallet out.
In the current contentious political environment, we've kept our eyes on all things for women and women's health. Turns out, Sheryl Sandberg does too: Refinery 29 reports Sheryl Sandberg donated $1 million to Planned Parenthood.
Sandberg is just one of many to join the organization's increasing swell of donors who have contributed to Planned Parenthood with awakened fervor in the months since President Donald Trump's election and the reaffirmation of the GOP majority. In the six weeks following Trump's victory, Planned Parenthood received 300,000 donations—about 40 times the amount of the organization's normal rate. The influx of private money is desperately needed, as the GOP has made defunding Planned Parenthood as one part of its plan to repeal President Barack Obama's Affordable Care Act—despite the essential health services Planned Parenthood provides to 2.5 million Americans annually including a slew of gynecological, psychological, and family health and planning services.
Planned Parenthood president Cecile Richards (one of the many incredible speakers a few weeks back at The Women's March on Washington) told Refinery29 that she's grateful for the "longstanding, and now increased, support" of Sandberg, who is still the COO of Facebook. Richards added that even as the federal government threatens to strip the organization of more funding than it can reasonably hope to replace privately, "we will never stop fighting for our patients and we thank everyone who, like Sheryl, has redoubled their commitment during this fight."
Although Sandberg's feminist legacy is a bit complicated (her much-talked about Lean In movement had women divided, for example; she also visited Trump Tower in December). But most recently, Sandberg spoke out when Trump reinstated the global gag rule, thereby cutting off funding to NGOs that provide abortions or even abortion counseling. In a (what else?) Facebook post, Sandberg wrote, "Women's rights are human rights—and there is no more basic right than health care. Women around the world deserve our support."
Hey Sheryl? On this one, we're totally with you.


text:
Jorge Brovetto (14 February 1933 – 8 June 2019) was a Uruguayan chemical engineer, academic and politician.

He successively served as President of the Broad Front, as Rector of the University of the Republic, and as Minister of Education and Culture.

References

External links

1933 births
2019 deaths
People from Montevideo
University of the Republic (Uruguay) alumni
Uruguayan chemical engineers
University of the Republic (Uruguay) rectors
Broad Front (Uruguay) politicians
Education and Culture Ministers of Uruguay